Hodgkin Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Lymphoma (1022)

Non-Hodgkin’s Lymphoma (887)

Lymphoma (1022)

Non-Hodgkin’s Lymphoma (887)

›

No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	Bv-AVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) Bv-AVE-PC Sensitive : A2 NCCN - 3wk	Bv-AVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks Bv-AVE-PC Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	AEPA-CAPDAC Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) AEPA-CAPDAC Sensitive : A2 NCCN - 3wk	AEPA-CAPDAC Sensitive: A2 - Guideline NCCN - 3 weeks AEPA-CAPDAC Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	CVbP Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) CVbP Sensitive : A2 NCCN - 3wk	CVbP Sensitive: A2 - Guideline NCCN - 3 weeks CVbP Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	CHOP Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) CHOP Sensitive : A2 NCCN - 3wk	CHOP Sensitive: A2 - Guideline NCCN - 3 weeks CHOP Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	OEPA Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) OEPA Sensitive : A2 NCCN - 3wk	OEPA Sensitive: A2 - Guideline NCCN - 3 weeks OEPA Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	ABVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) ABVE-PC Sensitive : A2 NCCN - 3wk	ABVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks ABVE-PC Sensitive : A2 NCCN - 3 weeks - (New A2)
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	penpulimab Sensitive: A1 - Approval penpulimab Sensitive : A1	penpulimab Sensitive: A1 - Approval penpulimab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	AB122 Sensitive: A1 - Approval AB122 Sensitive : A1	AB122 Sensitive: A1 - Approval AB122 Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	R-CVP Sensitive: A2 - Guideline R-CVP Sensitive : A2	R-CVP Sensitive: A2 - Guideline R-CVP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline carboplatin + etoposide oral + bendamustine Sensitive : A2	carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline carboplatin + etoposide oral + bendamustine Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline nivolumab + brentuximab vedotin Sensitive : A2	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline nivolumab + brentuximab vedotin Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	ICE Sensitive: A2 - Guideline ICE Sensitive : A2	ICE Sensitive: A2 - Guideline ICE Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	DHAP Sensitive: A2 - Guideline DHAP Sensitive : A2	DHAP Sensitive: A2 - Guideline DHAP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	MINE Sensitive: A2 - Guideline MINE Sensitive : A2	MINE Sensitive: A2 - Guideline MINE Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	BEACOPP Sensitive: A2 - Guideline BEACOPP Sensitive : A2	BEACOPP Sensitive: A2 - Guideline BEACOPP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	IGEV Sensitive: A2 - Guideline IGEV Sensitive : A2	IGEV Sensitive: A2 - Guideline IGEV Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	GVD Sensitive: A2 - Guideline GVD Sensitive : A2	GVD Sensitive: A2 - Guideline GVD Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	GDP Sensitive: A2 - Guideline GDP Sensitive : A2	GDP Sensitive: A2 - Guideline GDP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	EPIC Sensitive: A2 - Guideline EPIC Sensitive : A2	EPIC Sensitive: A2 - Guideline EPIC Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	BEAM Sensitive: A2 - Guideline BEAM Sensitive : A2	BEAM Sensitive: A2 - Guideline BEAM Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	rituximab/hyaluronidase Sensitive: A2 - Guideline rituximab / hyaluronidase Sensitive : A2	rituximab/hyaluronidase Sensitive: A2 - Guideline rituximab / hyaluronidase Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	vinblastine Sensitive: A2 - Guideline vinblastine Sensitive : A2	vinblastine Sensitive: A2 - Guideline vinblastine Sensitive : A2
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2
CHD8 mutation	Hodgkin Lymphoma	CHD8 mutation	Hodgkin Lymphoma	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3
CELF2 mutation	Hodgkin Lymphoma	CELF2 mutation	Hodgkin Lymphoma	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3
ABCC2 underexpression	Hodgkin Lymphoma	ABCC2 underexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3

Hodgkin Lymphoma

Associations(59)

Associations
(59)